title: [Risk factors for Abacavir-induced hypersensibility syndrome in the "real world"].
abstract: Abacavir (ABC) is a generally well-tolerated NRTI. However, up to 5% of patients may develop hypersensitivity syndrome (HSS) within the first weeks of treatment. The objectives of this study were to describe the side effects of ABC, to evaluate the incidence of the ABC-HSS, and to identify the risk factors of HSS after first exposure to ABC in a cohort of patients followed up in a university HIV clinic.
  
  
  METHODS
  The charts of all HIV-infected patients who started ABC between February 1998 and May 2002 were reviewed. HSS was defined as the onset, within 8 weeks of ABC initiation, of either a skin rash associated with at least one of the following symptoms (fever, gastrointestinal symptoms, respiratory symptoms, myalgia, malaise) or at least three of the above symptoms in the absence of rash. A multivariate logistic regression analysis was performed to identify risk factors of HSS.
  
  
  RESULTS
  Of the 191 patients studied (134 M, 57 F, mean age 39 years), 53 (27.8%) presented with manifestations that were regarded as potential side-effects of ABC. Ten (5.2%) developed HSS, none of whom died. Two factors were independently associated with an increased risk of HSS: history of allergy to nevirapine (OR 8.1, 95% CI 1.6-40.5, p = 0.02), and being naïve to ART (OR 5.8, 95% CI 1.2-28.5, p = 0.04).
  
  
  CONCLUSIONS
  This study "in the real world" confirms that the incidence of ABC-induced HSS is of about 5%. It also confirms that HSS occurs more frequently in patients with a history of allergy to nevirapine and in ART-naïve patients.
authors.affiliation: Service des maladies infectieuses, CHU Saint-Jacques, place Saint-Jacques, 25030 Besançon, France. cchirouze@chu-besancon.fr
authors.forename: C
authors.initials: C
authors.lastname: Chirouze
authors.forename: L
authors.initials: L
authors.lastname: Hustache-Mathieu
authors.forename: C
authors.initials: C
authors.lastname: Rougeot
authors.forename: C
authors.initials: C
authors.lastname: Drobacheff
authors.forename: H
authors.initials: H
authors.lastname: Gil
authors.forename: J P
authors.initials: JP
authors.lastname: Faller
authors.forename: C
authors.initials: C
authors.lastname: Lebrun
authors.forename: J M
authors.initials: JM
authors.lastname: Estavoyer
authors.forename: T
authors.initials: T
authors.lastname: Hénon
authors.forename: B
authors.initials: B
authors.lastname: Hoen
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D015224:Dideoxynucleosides / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000453:epidemiology*; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D012307:Risk Factors; D013577:Syndrome; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir